Chemical | 12 April 2021
Clariant opens JV facility for high-end stabilizer additives production in China
Facility is the centerpiece of the cooperation between Clariant and Tiangang
Facility is the centerpiece of the cooperation between Clariant and Tiangang
The company has received a certificate of Good Manufacturing Practice compliance from the Medicines & Healthcare products Regulatory Agency (MHRA) UK
The expansion will maintain zero liquid discharge norms by deploying innovative technology i.e. SHIFT, developed in Praj’s R&D facility
The company received the award in the “Engineering” category as it touches the lives of 2 million people spread across 46 districts in India
WTO should take proactive steps towards its modernization in several key areas
The transaction will close after regulatory approval, which is estimated to the second quarter of 2021.
Superior received $600 million in cash proceeds from Birch Hill
The approval is for Ibrutinib tablets 560 mg, 420 mg, 280 mg and 140 mg strengths
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
Consent capacities of all co-products have also been enhanced by the company
The centre has an area of over 6,000 square meter and is ready to provide leadership in research and development for both Performance Elastomers and Functional Solutions business units
SADIG-ILCO’s new PlasChem Park facility will offtake Ethylene Oxide (EO) and Propylene Oxide (PO) from Sadara through the new EO and PO pipelines that are being built by Sadara
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
The government has taken all the effective measures to make healthcare affordable
Parfex creates fragrances principally for premium personal care and fine perfumery markets, leveraging the natural raw materials that are available in the region
Many of the world’s leading consumer brands have pledged to increase the amount of PCR content in plastic packaging to an average of 25 percent by 2025
Over the tenure of the contract, the company expects to generate revenues of approximately ?225-250 crores.
Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg.
Sapropterin dihydrochloride powder for oral solution is available in 100 mg unit dose
Achieving the industry’s ambitious growth targets will require a combination of policy intervention, company-level initiatives, industry-academic partnerships, wise investments, and greater international access
Subscribe to our newsletter & stay updated.
